Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

A Novel Nanoprobe for Multimodal Imaging Is Effectively Incorporated into Human Melanoma Metastatic Cell Lines

SN. Aasen, A. Pospisilova, TW. Eichler, J. Panek, M. Hruby, P. Stepanek, E. Spriet, D. Jirak, KO. Skaftnesmo, F. Thorsen,

. 2015 ; 16 (9) : 21658-80. [pub] 20150908

Jazyk angličtina Země Švýcarsko

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc16020295

Grantová podpora
NV15-25781A MZ0 CEP - Centrální evidence projektů

To facilitate efficient drug delivery to tumor tissue, several nanomaterials have been designed, with combined diagnostic and therapeutic properties. In this work, we carried out fundamental in vitro and in vivo experiments to assess the labeling efficacy of our novel theranostic nanoprobe, consisting of glycogen conjugated with a red fluorescent probe and gadolinium. Microscopy and resazurin viability assays were used to study cell labeling and cell viability in human metastatic melanoma cell lines. Fluorescence lifetime correlation spectroscopy (FLCS) was done to investigate nanoprobe stability. Magnetic resonance imaging (MRI) was performed to study T₁ relaxivity in vitro, and contrast enhancement in a subcutaneous in vivo tumor model. Efficient cell labeling was demonstrated, while cell viability, cell migration, and cell growth was not affected. FLCS showed that the nanoprobe did not degrade in blood plasma. MRI demonstrated that down to 750 cells/μL of labeled cells in agar phantoms could be detected. In vivo MRI showed that contrast enhancement in tumors was comparable between Omniscan contrast agent and the nanoprobe. In conclusion, we demonstrate for the first time that a non-toxic glycogen-based nanoprobe may effectively visualize tumor cells and tissue, and, in future experiments, we will investigate its therapeutic potential by conjugating therapeutic compounds to the nanoprobe.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc16020295
003      
CZ-PrNML
005      
20201014141847.0
007      
ta
008      
160722s2015 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3390/ijms160921658 $2 doi
024    7_
$a 10.3390/ijms160921658 $2 doi
035    __
$a (PubMed)26370983
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Aasen, Synnøve Nymark $u NorLux Neuro-Oncology Laboratory, Department of Biomedicine, University of Bergen, 5020 Bergen, Norway. synnovenymarkaasen@gmail.com. $7 gn_A_00000121
245    12
$a A Novel Nanoprobe for Multimodal Imaging Is Effectively Incorporated into Human Melanoma Metastatic Cell Lines / $c SN. Aasen, A. Pospisilova, TW. Eichler, J. Panek, M. Hruby, P. Stepanek, E. Spriet, D. Jirak, KO. Skaftnesmo, F. Thorsen,
520    9_
$a To facilitate efficient drug delivery to tumor tissue, several nanomaterials have been designed, with combined diagnostic and therapeutic properties. In this work, we carried out fundamental in vitro and in vivo experiments to assess the labeling efficacy of our novel theranostic nanoprobe, consisting of glycogen conjugated with a red fluorescent probe and gadolinium. Microscopy and resazurin viability assays were used to study cell labeling and cell viability in human metastatic melanoma cell lines. Fluorescence lifetime correlation spectroscopy (FLCS) was done to investigate nanoprobe stability. Magnetic resonance imaging (MRI) was performed to study T₁ relaxivity in vitro, and contrast enhancement in a subcutaneous in vivo tumor model. Efficient cell labeling was demonstrated, while cell viability, cell migration, and cell growth was not affected. FLCS showed that the nanoprobe did not degrade in blood plasma. MRI demonstrated that down to 750 cells/μL of labeled cells in agar phantoms could be detected. In vivo MRI showed that contrast enhancement in tumors was comparable between Omniscan contrast agent and the nanoprobe. In conclusion, we demonstrate for the first time that a non-toxic glycogen-based nanoprobe may effectively visualize tumor cells and tissue, and, in future experiments, we will investigate its therapeutic potential by conjugating therapeutic compounds to the nanoprobe.
650    _2
$a nádorové buněčné linie $7 D045744
650    _2
$a pohyb buněk $7 D002465
650    _2
$a viabilita buněk $7 D002470
650    _2
$a kontrastní látky $x chemie $7 D003287
650    _2
$a cytoplazma $x metabolismus $7 D003593
650    _2
$a glykogen $x metabolismus $7 D006003
650    _2
$a lidé $7 D006801
650    _2
$a koncentrace vodíkových iontů $7 D006863
650    _2
$a lyzozomy $x metabolismus $7 D008247
650    _2
$a magnetická rezonanční tomografie $x metody $7 D008279
650    _2
$a melanom $x metabolismus $x patologie $7 D008545
650    _2
$a molekulární zobrazování $x metody $7 D057054
650    12
$a molekulární sondy $7 D015335
650    12
$a multimodální zobrazování $7 D064847
650    12
$a nanotechnologie $7 D036103
650    _2
$a fluorescenční spektrometrie $7 D013050
650    _2
$a barvení a značení $7 D013194
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Pospisilova, Aneta $u Institute of Macromolecular Chemistry, Academy of Sciences of the Czech Republic, 162 06 Prague, Czech Republic. pospisilova-a@seznam.cz.
700    1_
$a Eichler, Tilo Wolf $u Department of Clinical Medicine, University of Bergen, 5020 Bergen, Norway. tilo.eichler@k1.uib.no.
700    1_
$a Panek, Jiri $u Institute of Macromolecular Chemistry, Academy of Sciences of the Czech Republic, 162 06 Prague, Czech Republic. panek@imc.cas.cz.
700    1_
$a Hruby, Martin $u Institute of Macromolecular Chemistry, Academy of Sciences of the Czech Republic, 162 06 Prague, Czech Republic. mhruby@centrum.cz.
700    1_
$a Stepanek, Petr $u Institute of Macromolecular Chemistry, Academy of Sciences of the Czech Republic, 162 06 Prague, Czech Republic. ppetr.stepanek@gmail.com.
700    1_
$a Spriet, Endy $u Molecular Imaging Center, Department of Biomedicine, University of Bergen, 5020 Bergen, Norway. endy.spriet@uib.no.
700    1_
$a Jirak, Daniel $u Department of Diagnostic and Interventional Radiology, Institute for Clinical and Experimental Medicine, 140 21 Prague, Czech Republic. daji@medicon.cz. Institute of Biophysics and Informatics, 1st Medicine Faculty, Charles University, 120 00 Prague, Czech Republic. daji@medicon.cz.
700    1_
$a Skaftnesmo, Kai Ove $u NorLux Neuro-Oncology Laboratory, Department of Biomedicine, University of Bergen, 5020 Bergen, Norway. kaioveskaftnesmo@gmail.com.
700    1_
$a Thorsen, Frits $u NorLux Neuro-Oncology Laboratory, Department of Biomedicine, University of Bergen, 5020 Bergen, Norway. frits.thorsen@uib.no. Molecular Imaging Center, Department of Biomedicine, University of Bergen, 5020 Bergen, Norway. frits.thorsen@uib.no. Kristian Gerhard Jebsen Brain Tumour Research Centre, Department of Biomedicine, University of Bergen, 5020 Bergen, Norway. frits.thorsen@uib.no.
773    0_
$w MED00176142 $t International journal of molecular sciences $x 1422-0067 $g Roč. 16, č. 9 (2015), s. 21658-80
856    41
$u https://pubmed.ncbi.nlm.nih.gov/26370983 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20160722 $b ABA008
991    __
$a 20201014141844 $b ABA008
999    __
$a ok $b bmc $g 1154965 $s 944823
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2015 $b 16 $c 9 $d 21658-80 $e 20150908 $i 1422-0067 $m International journal of molecular sciences $n Int J Mol Sci $x MED00176142
GRA    __
$a NV15-25781A $p MZ0
LZP    __
$a Pubmed-20160722

Najít záznam

Citační ukazatele

Možnosti archivace